{
    "nctId": "NCT05223322",
    "briefTitle": "Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction",
    "officialTitle": "DECODE Heartland: Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "Maximal Exercise: Maximal oxygen consumption will be evaluated using cycle ergometry or treadmill to exhaustion as described in the Integrative Physiology Laboratory at each testing visit.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult (\u2265 18 years) assigned female sex at birth\n* Diagnosed with invasive non-metastatic breast cancer\n* Receiving neo-adjuvant CTx (or adjuvant CTx and undergoing breast conserving surgery) that includes anthracyclines (such as DOX) and/or targeted anti-Her2 therapy\n* Able to safely participate in moderate exercise and strength training based on MD approval\n* Willing to complete all study activities\n* Self-identifies as Black/African American or non-Hispanic White\n\nExclusion Criteria:\n\n* Unintentional weight loss \\> 10% in the past 6 months\n* Current pregnant and lactating patients. Must have completed lactation prior to study start\n* Metastatic disease\n* Diagnosed cardiovascular disease as evidenced by cardiomyopathy (reduced regional or global LV contractility), diastolic dysfunction grade 2 or above, symptomatic coronary - artery disease, ejection fraction below 50%\n* History of prior chemotherapy or targeted H2N Treatment received less than 3 years ago\n* Non-English speaking",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}